CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies | Pierre Fabre Pharma Norden AB
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Puma licences breast cancer therapy Nerlynx to Pierre Fabre in Europe
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
Pierre Fabre étend sa collaboration avec Puma Biotechnology
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
Partners of the Pierre Fabre Group: from health to beauty
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology, Pierre Fabre enter into Exclusive License Agreement
Partners of the Pierre Fabre Group: from health to beauty
Puma Biotech Expands Pierre Fabre License to Add Countries
Pierre Fabre engagements | NERLYNX
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma regains China rights to Nerlynx and amends deal with Fabre
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Pierre Fabre pens oncology pact with atomic energy spinout | Fierce Biotech
Puma Biotechnology | Evaluate
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Bio: A Contrarian Investment That Requires Patience (NASDAQ:PBYI) | Seeking Alpha
Puma regains China rights to Nerlynx and amends deal with Fabre
